References
Alberts, D.S., Liu, P.Y., Hannigan, E.T., O'Toole, R., Williams, S., Young, J.A., … DuBeshler, B. (1996). Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New England Journal of Medicine, 335, 1950-1955. doi:10.1056/NEJM199612263352603
Almadrones, L. (2007). Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer. Clinical Journal of Oncology Nursing, 11, 211-216. doi:10.1188/07.CJON.211-216
Anderson, N., & Hacker, E.D. (2008). Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: A review of contributing factors. Clinical Journal of Oncology Nursing, 12, 445-454. doi:10.1188/08.CJON.445-454
Armstrong, D.K., Bundy, B., Wenzel, L., Huang, H.Q., Baergan, R., Lele, S., & Burger, R.A. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, 354, 34-43.
Eisenhauer, E.A., ten Bokkel Huinink, W.W., Swenerton, K.D., Gianni, L., Myles, J., van der Burg, M.D., … Columbo, N. (1994). European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long-versus-short infusion. Journal of Clinical Oncology, 12, 2654-2666.
Hydzik, C. (2007). Implementation of intraperitoneal chemotherapy for the treatment of ovarian cancer. Clinical Journal of Oncology Nursing, 11, 221-225. doi:10.1188/07.CJON.221-225
Kiser, D., Greer, T.B., Wilmoth, M.C., Dmochowski, J., & Naumann, R.W. (2010). Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments. Oncology Nursing Forum, 37, 758-764. doi:10.1188/10.ONF.758-764
Markman, M., Bundy, B.N., Alberts, D.S., Fowler, J.M., Clark-Pearson, D.L., Carson, L.F., … Sickel, J. (2001). Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage II ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 19, 1001-1007.
Markman, M., & Walker, J.L. (2006). Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. Journal of Clinical Oncology, 24, 988-994.
National Cancer Institute. (2006). Abdominal chemotherapy for ovarian cancer improves survival. NCI Cancer Bulletin, 3(2), 1.
Potter, K., & Held-Warmkessel, J. (2008). Intraperitoneal chemotherapy in women with ovarian cancer: Nursing care and considerations. Clinical Journal of Oncology Nursing, 12, 265-271. doi:10.1188/08.CJON.265-271
Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29. doi:10.3322/caac.20138/08
Wenzel, L.B., Huang, H.Q., Armstrong, D.K., Walker, J.L., & Cella, D. (2007). Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group study. Journal of Clinical Oncology, 25, 437-443.
Alberts, D.S., Liu, P.Y., Hannigan, E.T., O'Toole, R., Williams, S., Young, J.A., … DuBeshler, B. (1996). Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New England Journal of Medicine, 335, 1950-1955. doi:10.1056/NEJM199612263352603
Almadrones, L. (2007). Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer. Clinical Journal of Oncology Nursing, 11, 211-216. doi:10.1188/07.CJON.211-216
Anderson, N., & Hacker, E.D. (2008). Fatigue in women receiving intraperi-toneal chemotherapy for ovarian cancer: A review of contributing factors. Clinical Journal of Oncology Nursing, 12, 445-454. doi:10.1188/08.CJON.445-454
Armstrong, D.K., Bundy, B., Wenzel, L., Huang, H.Q., Baergan, R., Lele, S., & Burger, R.A. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, 354, 34-43. doi:10.1056/NEJMoa052985
Eisenhauer, E.A., ten Bokkel Huinink, W.W., Swenerton, K.D., Gianni, L., Myles, J., van der Burg, M.D., … Columbo, N. (1994). European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology, 12, 2654-2666.
Markman, M., Bundy, B.N., Alberts, D.S., Fowler, J.M., Clark-Pearson, D.L., Carson, L.F., … Sickel, J. (2001). Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage II ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 19, 1001-1007.
Potter, K., & Held-Warmkessel, J. (2008). Intraperitoneal chemotherapy in women with ovarian cancer: Nursing care and considerations. Clinical Journal of Oncology Nursing, 12, 265-271. doi:10.1188/08.CJON.265-271